Myocarditis from COVID-19 booster rare, but risk highest among teen boys, young men | American Heart Association
Vaccines | Free Full-Text | Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Myocarditis With COVID-19 mRNA Vaccines | Circulation
Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions | Nature Reviews Cardiology
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study | PLOS Medicine
More Evidence Links Myocarditis to mRNA COVID-19 Vaccines | tctmd.com
Heart inflammation risk remains rare after third COVID-19 vaccine dose | American Heart Association
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Myocarditis Risk Remains Rare After Third mRNA Vaccine Dose | tctmd.com
Israel reports very few myocarditis cases among 12-15 year olds after booster | Reuters
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study | The BMJ
COVID-19 Vaccine Boosters vs. Third Doses: Frequently Asked Questions - Anne Arundel County Department of Health
Myocarditis low after COVID-19 vaccination, but odds elevated in male teens, young adults
Frontiers | A Case Series of Myocarditis Following Third (Booster) Dose of COVID-19 Vaccination: Magnetic Resonance Imaging Study
RACGP - COVID risk calculator updated to include Pfizer vaccine, myocarditis probability
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC ...
Vaccines | Free Full-Text | Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study | PLOS Medicine
Study Finds That Risk of Myocarditis After SARS-CoV-2 Vaccination is Increased But Very Low | DAIC
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022 | MMWR
